Product Description
Mechanisms of Action: 5-HT2A Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Sanofi
Company Location: PARIS I0 75008
Company CEO: Paul Hudson
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Insomnia
Phase 2: Parasomnias|Chronic Pain|Fibromyalgia|Myofascial Pain Syndromes
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|
| 2014-004644-35 | P1 |
Terminated |
Insomnia |
2013-02-25 |
2025-06-05 |
Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
| PKiDs | P1 |
Completed |
Insomnia |
2009-12-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| ECLIPSE | P3 |
Completed |
Insomnia |
2009-06-05 |
2022-03-12 |
Treatments |
|
| ECLIPSE | P3 |
Completed |
Insomnia |
2009-06-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| DREAMS | P3 |
Completed |
Insomnia |
2009-03-06 |
2022-03-12 |
Treatments |
|
| DREAMS | P3 |
Completed |
Insomnia |
2009-03-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| EPLILONG | P3 |
Completed |
Insomnia |
2008-09-10 |
2022-03-12 |
Treatments |
|
| GEMS | P3 |
Completed |
Insomnia |
2008-01-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| EPLILONG | P3 |
Completed |
Insomnia |
2007-11-01 |
2024-10-16 |
Primary Endpoints|Treatments |
|
| GEMS | P3 |
Completed |
Insomnia |
2007-10-16 |
2022-03-12 |
Treatments |
|
| EPOCH | P3 |
Completed |
Insomnia |
2007-08-01 |
2024-10-16 |
Primary Endpoints |
|
| ACT5400 | P2 |
Completed |
Parasomnias|Myofascial Pain Syndromes|Chronic Pain|Fibromyalgia |
2005-06-01 |
2024-10-16 |
Primary Endpoints |
Recent News Events
Date |
Type |
Title |
|---|